Genmab is aiming to expand its late-stage pipeline and accelerate to a wholly owned model. The transaction received unanimous approval from both company’s board of directors, with Genmab conducting a tender offer for all of Merus’ common shares. “Petosemtamab has the potential to be a transformational therapy for patients living with head and neck cancer. Genmab is aiming to broaden and accelerate Petosemtamab’s development through its potential for expansion into earlier lines of therapy. Following its initial anticipated approval, Genmab believes Petosemtamab will be accretive to EBITDA with at least $1 billion in annual sales potential by 2029.